AU2001280091A1 - Inhibitors of cellular efflux pumps of microbes - Google Patents
Inhibitors of cellular efflux pumps of microbesInfo
- Publication number
- AU2001280091A1 AU2001280091A1 AU2001280091A AU8009101A AU2001280091A1 AU 2001280091 A1 AU2001280091 A1 AU 2001280091A1 AU 2001280091 A AU2001280091 A AU 2001280091A AU 8009101 A AU8009101 A AU 8009101A AU 2001280091 A1 AU2001280091 A1 AU 2001280091A1
- Authority
- AU
- Australia
- Prior art keywords
- microbes
- inhibitors
- efflux pumps
- cellular efflux
- cellular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001413 cellular effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
- C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22220100P | 2000-08-01 | 2000-08-01 | |
| US60/222,201 | 2000-08-01 | ||
| US09/640,947 US6750224B1 (en) | 1999-05-07 | 2000-08-17 | Antibacterial optically pure benzoquinolizine carboxylic acids, processes, compositions and methods of treatment |
| US09/640,947 | 2000-08-17 | ||
| IN0000111 | 2000-11-22 | ||
| INPCT/IN00/00111 | 2000-11-22 | ||
| US28629101P | 2001-04-25 | 2001-04-25 | |
| US60/286,291 | 2001-04-25 | ||
| US09/850,669 US6608078B2 (en) | 2000-05-08 | 2001-05-07 | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment |
| US09/850,669 | 2001-05-07 | ||
| PCT/IN2001/000100 WO2001085728A2 (fr) | 2000-05-08 | 2001-05-08 | Piperidino-benzo [i, j] quinolizines a substitution de piperidino en 8 chirales antibacteriennes, procedes, compositions et methodes de traitement |
| AU78667/01 | 2001-05-08 | ||
| PCT/IN2001/000139 WO2002009758A2 (fr) | 2000-08-01 | 2001-07-31 | Inhibiteurs de pompes d'efflux cellulaire de microbes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001280091A1 true AU2001280091A1 (en) | 2002-02-13 |
Family
ID=27517699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001280091A Abandoned AU2001280091A1 (en) | 2000-08-01 | 2001-07-31 | Inhibitors of cellular efflux pumps of microbes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1305048A2 (fr) |
| AU (1) | AU2001280091A1 (fr) |
| CA (1) | CA2417799A1 (fr) |
| WO (1) | WO2002009758A2 (fr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6608078B2 (en) | 2000-05-08 | 2003-08-19 | Wockhardt Limited | Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment |
| US7098219B2 (en) | 2000-08-01 | 2006-08-29 | Wockhart Limited | Inhibitors of cellular efflux pumps of microbes |
| WO2011101710A1 (fr) * | 2010-02-16 | 2011-08-25 | Wockhardt Research Centre | Inhibiteurs de pompe à écoulement |
| US6878713B2 (en) | 2001-04-25 | 2005-04-12 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| US6964966B2 (en) * | 2001-04-25 | 2005-11-15 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| AU2002361493A1 (en) * | 2001-12-13 | 2003-06-23 | Wockhardt Limited | New generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
| EP1918289A3 (fr) * | 2002-05-28 | 2009-08-19 | Wockhardt Limited | Forme cristalline de sel d'arginine de fluoroquinolone |
| WO2003099815A1 (fr) | 2002-05-28 | 2003-12-04 | Wockhardt Limited | Forme cristalline de sel d'arginine de fluoroquinolone |
| US7829543B2 (en) | 2003-01-07 | 2010-11-09 | Paratek Pharmaceuticals, Inc. | Substituted polyamines as inhibitors of bacterial efflux pumps |
| GB2403653A (en) * | 2003-07-10 | 2005-01-12 | Secr Defence | Use of fluoroquinone antibiotics for the treatment of plague |
| EP1660495B1 (fr) * | 2003-09-04 | 2007-07-11 | Wockhardt Limited | Arginine tetrahydrate d'acide benzoquinolizine-2-carboxylique |
| WO2005026145A2 (fr) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Agents antibacteriens a base de quinolone |
| US7238694B2 (en) | 2004-01-13 | 2007-07-03 | Cumbre Pharmaceuticals, Inc. | Rifamycin imino derivatives effective against drug-resistant microbes |
| WO2005070940A2 (fr) * | 2004-01-13 | 2005-08-04 | Cumbre Pharmaceuticals Inc. | Derives de rifamycine efficaces contre des microbes pharmacoresistants |
| US7994225B2 (en) | 2004-03-17 | 2011-08-09 | Rempex Pharmaceuticals, Inc. | Bacterial efflux pump inhibitors for the treatment of ophthalmic and otic infections |
| JP2008500965A (ja) | 2004-03-17 | 2008-01-17 | エムペックス・ファーマシューティカルズ・インコーポレーテッド | 細菌の排出ポンプ阻害剤の使用および投与 |
| DE102004035203A1 (de) | 2004-07-21 | 2006-02-16 | Bayer Healthcare Ag | Substituierte Chinolone |
| DE102005030524A1 (de) | 2005-06-30 | 2007-01-18 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone II |
| DE102006005861A1 (de) | 2006-02-09 | 2007-08-23 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone III |
| CA2642264A1 (fr) | 2006-02-13 | 2007-08-30 | Trustees Of Boston University | Inhibiteurs reca a activite antibiotique, compositions et methodes d'utilisation |
| KR20130128483A (ko) * | 2006-03-07 | 2013-11-26 | 욱크하트 리미티드 | 벤조퀴놀리진-2-카르복실산의 프로드러그 |
| ES2427247T3 (es) * | 2006-03-13 | 2013-10-30 | Kyorin Pharmaceutical Co., Ltd. | Aminoquinolonas como inhibidores de GSK-3 |
| US20100234348A1 (en) * | 2006-08-04 | 2010-09-16 | Trustees Of Boston University | Compositions and methods for potentiating antibiotic activity |
| US7902227B2 (en) | 2007-07-27 | 2011-03-08 | Janssen Pharmaceutica Nv. | C-7 isoxazolinyl quinolone / naphthyridine derivatives useful as antibacterial agents |
| CN101855228B (zh) | 2007-09-11 | 2012-10-24 | 杏林制药株式会社 | 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮 |
| CN102344457B (zh) | 2007-09-12 | 2015-07-22 | 杏林制药株式会社 | 作为 gsk-3 抑制剂的螺环状氨基喹诺酮 |
| CN102421784B (zh) | 2009-03-11 | 2015-09-30 | 杏林制药株式会社 | 作为gsk-3抑制剂的7-环烷基氨基喹诺酮 |
| SI2751083T1 (en) | 2011-08-31 | 2018-04-30 | Otsuka Pharmaceutical Co., Ltd. | Quinolone compound |
| CN103183684B (zh) * | 2011-12-29 | 2015-11-18 | 杭州师范大学 | 一种喹喏酮内酯化合物及其制备方法和应用 |
| CN109486739B (zh) * | 2018-11-23 | 2022-02-01 | 上海海洋大学 | 一种诱导副溶血性弧菌产生左氧氟沙星耐药性的方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU200917B (en) * | 1987-07-20 | 1990-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical compositions comprising quinoline or naphthyridinecarboxylic acid and tetracycline derivatives as active ingredient |
| US5753269A (en) * | 1995-12-27 | 1998-05-19 | Bayer Corporation | Otic microbial combinations |
-
2001
- 2001-07-31 AU AU2001280091A patent/AU2001280091A1/en not_active Abandoned
- 2001-07-31 EP EP01958373A patent/EP1305048A2/fr not_active Withdrawn
- 2001-07-31 WO PCT/IN2001/000139 patent/WO2002009758A2/fr not_active Ceased
- 2001-07-31 CA CA002417799A patent/CA2417799A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2417799A1 (fr) | 2002-02-07 |
| WO2002009758A3 (fr) | 2002-12-27 |
| EP1305048A2 (fr) | 2003-05-02 |
| WO2002009758A2 (fr) | 2002-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001280091A1 (en) | Inhibitors of cellular efflux pumps of microbes | |
| AU5207399A (en) | Efflux pump inhibitors | |
| AU2001296961A1 (en) | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors | |
| AU2001273040A1 (en) | Factor xa inhibitors | |
| AU2002350217A1 (en) | Glycinamides as factor xa inhibitors | |
| AU2001234689A1 (en) | Bivalent phenylene inhibitors of factor xa | |
| AU2001258771A1 (en) | -secretase inhibitors | |
| AU2002356762A1 (en) | 4-arylquinazolines and use thereof as nhe-3 inhibitors | |
| AU2001293373A1 (en) | 2-guanidino-4-arylchinazolines as NHE-3 inhibitors | |
| AU2001234088A1 (en) | TNF-alpha inhibitors | |
| AU2337599A (en) | Efflux pump inhibitors | |
| AU2002367129A1 (en) | Organ fibrosis inhibitors | |
| AU2002367199A1 (en) | Cellular information terminal | |
| AU2001270580A1 (en) | Benzodiazepines as inhibitors of hpv e1 helicase | |
| AU2002254212A1 (en) | Identification of cellular targets for biologically active molecules | |
| AU2002211370A1 (en) | Inhibition of tgf-beta and uses thereof | |
| AU2001296907A1 (en) | New cellular architecture | |
| AU2002336746A1 (en) | Inhibitors of rnase p proteins as antibacterial compounds | |
| AU2002338734A1 (en) | Use of phosphorodiesterase IV inhibitors | |
| AU2001232245A1 (en) | Tnf- alpha inhibitors | |
| AU2002222933A1 (en) | Inhibitors of factor xa | |
| AU2001238027A1 (en) | Cellular coupon system | |
| AU2002332441A1 (en) | Mre11: modulation of cellular proliferation | |
| AU2002222628A1 (en) | Keratinocyte proliferation inhibitors | |
| AU2002223545A1 (en) | Delivery of location-specific information |